Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok(Chinese University of Hong Kong), Vassiliki A. Papadimitrakopoulou(Pfizer (United States)), Alison Templeton(AstraZeneca (United Kingdom)), Willemijn S.M.E. Theelen(Army Medical University), Myung‐Ju Ahn(Sungkyunkwan University), Serban Ghiorghiu(AstraZeneca (United Kingdom)), Hye Ryun Kim(Yonsei University), Chee Khoon Lee(The University of Sydney), Helen Mann(AstraZeneca (United Kingdom)), Frances A. Shepherd(University Health Network), Hiroaki Akamatsu(Army Medical University), Suresh S. Ramalingam(Emory University), Marina Chiara Garassino(University of Chicago), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Martin Sebastian(Goethe University Frankfurt), Marcelo Marotti(AstraZeneca (United Kingdom)), Yong He(Army Medical University)
Cited by 3,323
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k